Hilbrands, Luuk BDuivenvoorden, RaphaëlVart, PriyaFranssen, Casper F MHemmelder, Marc HJager, Kitty JKieneker, Lyanne MNoordzij, MarliesPena, Michelle JVries, Hanne deArroyo, DavidCovic, AdrianCrespo, MartaGoffin, EricIslam, MahmudMassy, Ziad AMontero, NuriaOliveira, João PRoca Muñoz, AnaSanchez, J EmilioSridharan, SivakumarWinzeler, RebeccaGansevoort, Ron TERACODA Collaborators2025-01-072025-01-072020https://hdl.handle.net/10668/24389Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3-30.2%] in kidney transplant and 25.0% (95% CI 20.2-30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59-1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.enCOVID-19dialysiskidneymortalitytransplantationAdultAge FactorsAgedAged, 80 and overCOVID-19Databases, FactualEuropeFemaleHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPrognosisProspective StudiesRenal DialysisRisk FactorsSARS-CoV-2Survival RateWaiting Listsresearch article33151337open access10.1093/ndt/gfaa2611460-2385PMC7665620https://academic.oup.com/ndt/article-pdf/35/11/1973/38396884/gfaa261.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7665620/pdf